The Neher Lab’s SARS-CoV-2 Variant Report dated April 23, 2025, provides an overview of the current landscape of SARS-CoV-2 variants, focusing on their prevalence, genetic characteristics, and potential public health implications.
🧬 Key Variants and Lineages
- JN.1: Remains the predominant variant globally. It is a descendant of the BA.2.86 lineage and is characterized by the S:L455S mutation.
- KP.3: A sublineage of JN.1, KP.3 carries additional mutations such as S:F456L, S:Q493E, and S:V1104L.
- XEC: A recombinant variant combining elements from KS.1.1 and KP.3.3 lineages. It has been designated as a Variant Under Monitoring (VUM) by the WHO due to its increased transmissibility and potential for immune evasion.
📈 Epidemiological Trends
- XEC and LP.8.1 are the only VUMs currently increasing in prevalence, accounting for 44.8% and 4.7% of sequences in early 2025, respectively. All other monitored variants are on the decline.
- XEC has been detected in 43 countries across Europe, Asia, and North America, indicating a widespread but uneven distribution.
🧪 Genetic Insights
- The mutation rate of SARS-CoV-2 varies significantly across different genomic sites, influenced by sequence context, genomic region, and RNA structure. Understanding these variations is crucial for modeling viral evolution and assessing the potential impact of emerging mutations.
🧭 Public Health Implications
- The continuous evolution of SARS-CoV-2 underscores the importance of sustained genomic surveillance to detect and assess emerging variants promptly.
- Variants like XEC, with increased transmissibility and immune evasion capabilities, highlight the need for ongoing evaluation of vaccine efficacy and potential updates to vaccine formulations.